news: January 24, 2008 - 9:39 AM EST Nano Chemical Systems Inc. Announces Letter of Intent to Acquire Calgenex Corporation Nano Chemical Systems Holdings, Inc. (Pink Sheets:NCSH), ("Nanochem" or "The Company") announced today that it has entered into a Letter of Intent with Calgenex Corporation ("Calgenex") for the acquisition of Calgenex by Nanochem. Calgenex develops and markets novel, patented or patent pending, condition specific dietary supplements and topical over-the-counter (OTC) drugs and personal care products. The products are scientifically formulated to help treat a variety of acute and chronic conditions. The products are marketed direct to physician resellers throughout the United States. In addition, the Company markets direct to consumers over the internet. “We are excited about the opportunity to bring a dynamic, market and scientific based company like Calgenex into Nanochem,” stated Alex H. Edwards III, Nanochem’s CEO. “They are seeking solutions for specific health conditions affecting the aging baby boomer population like Soft Tissue Calcification, Cholesterol, Osteoporosis, Psoriasis, and Eczema. These conditions represent an ever expanding part of healthcare expenditures,” concluded Edwards. “The move to the public marketplace has always been in our long term plans,” stated Grant Carlson, Calgenex president & CEO. “The increased access to capital, as well as the opportunity to create tremendous shareholder value, make the move into Nanochem a perfect fit.”
January 24, 2008 - 9:38 AM EST Nano Chemical Systems Inc. Announces New Business Direction Nano Chemical Systems Holdings, Inc. (Pink Sheets:NCSH), ("Nanochem" or "The Company") announces that it has executed an agreement for the dissolution of the “Agreement and Plan of Merger” signed on October 26, 2007 and mutual release with BioCentric Energy, Inc., (BCEI). The Company will now pursue business opportunities in the dietary supplement and topical over-the-counter (OTC) drug and personal care product arena. Nanochem anticipates immediate growth via acquisition in this $60 Billion worldwide market. “We wish BioCentric Energy, Inc. well as they pursue other opportunities,” stated Alex H. Edwards III, Nanochem’s CEO. “We have identified a new strategic direction and specifically targeted acquisitions that we are confident will create tremendous shareholder value in the very near term.”
PPS estimate - from IHUB (LOL) Posted by: alexindef In reply to: None Date:1/24/2008 9:18:15 PM Post #of 204
Caldenex (market potentials)
http://www.calgenex.com/omega3s.html "Triglyceride" is the chemical term for a specific type of fat found in the bloodstream. Triglycerides serve as important sources of fuel in normal metabolism. But some people manufacture too many triglycerides - and that puts their hearts at risk. It's estimated that as many as 47 million Americans have elevated triglycerides. If your doctor has informed you that you're one of them, there's a word you need to know: omega 3 fatty acids. What are Omega 3s? Omega 3s are good fats that are just as important to your health as vitamins and minerals. However, since your body can't manufacture them, you have to get omega 3s through your diet - and many people do not get enough. Why are omega 3s so important? Because they have been scientifically proven to lower triglycerides. In fact, a 1997 review study - which looked at the results of 65 human clinical trials on fish oil supplementation - concluded that about 3 grams a day of EPA + DHA reduced triglyceride levels 25-35%! The evidence is so strong that in 2002, the American Heart Association officially endorsed omega 3s (specifically EPA and DHA) for lowering triglycerides. And the FDA concluded that "supportive, but not conclusive evidence shows that consumption of EPA and DHA fatty acids may reduce the risk of coronary heart disease."
Fact: About 30% of American adults have total cholesterol levels above 200 mg/mL.
Caldenex products: Calci Clear $69.90 30 day supply Omeganol $39.95 30 day supply Dermalleve $12.95 bottle
Even for 1% of 47 million Americans with elevated triglycerides the monthly revenue for Omeganol will be: 470,000 * $39.95 = $18,776,500
Even for 1% of 80 million Americans with soft tissue calcification the monthly revenue for Omeganol will be: 800,000 * $69.90 = $55,920,000
At glance: 12 month * $74,696,500 = $896,358,000 WOW even 1% of potentials will give us: $8,963,580/year
EPS (for simplicity: dividents payment is equal 0) = $8,963,580 / 100,000,000 = $0.0896 PPS with multiplier of 12 is $0.0896 * 12 = $1.075
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
hard to compare any of these companies vs Caldenex without published financials of Caldenex (like comparing apples to oranges for now but worse to look at the public companies in the biotechnology and pharmaceutical industries to see the market caps, revenues and share structures vs Caldenex (undervalued at least 20X in raw estimate)
Posted by: alexindef In reply to: None Date:1/27/2008 6:23:48 PM Post #of 216
Caldenex - CEO
Grant Carlson - President & CEO at Calgenex Corporation
Grant Carlson - past(1): President & COO at Nanobac Pharmaceuticals
http://www.nanobac.comhttp://www.nanobaclabs.com/ Market Cap 11,631,265.122 as of Jan 25, 2008 October 03, 2007 12:00 AM Nanobac Pharmaceuticals Acquires Option to License Calgenex Technology to Treat Atherosclerosis and Prostatitis TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today that it signed an agreement with Calgenex granting Nanobac an option to assess Calgenex’ drug delivery technology for potential use with Nanobac’s drug combinations used in treating atherosclerosis, prostatitis, and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid. “Today’s option agreement is a testament towards our goal of evaluating the best therapeutic delivery technologies used with our compounds to treat diseases associated with pathologic calcification,” commented Alex H. Edwards III Director, Nanobac Pharmaceuticals. “We will be evaluating the Calgenex technology in the context of our drug development efforts in order to improve on an important class of drugs, namely bisphosphonates.”
more: Nanobac Announces European Heart Journal Publication of Association Between Calcifying Nanoparticles and Aortic Stenosis TAMPA, Fla., Jan 22, 2008 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces the multicenter publication of independent research which reports an association between calcifying nanoparticles (CNPs) and aortic stenosis. Aortic stenosis represents the most frequent cause of heart valve replacement (Bratos-Perez et al, European Heart Journal Advance Access, doi:10.1093/eurheartj/ehm592). The authors contend: "For the first time, this study shows that CNP could be causally related to aortic stenosis in humans. We suggest that CNPs colonize the aortic valve, provoking an inflammatory response, resulting in valve calcification via two distinct mechanisms: directly given their capacity to precipitate calcium in the shape of apatite crystals, at physiological calcium and phosphate concentrations, and indirectly by activating the inflammatory pathways."
Grant Carlson - past(3): Vice Pres., Marketing and Business Development at Dianon Systems http://www.dianon.com/Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
"Nano Chemical Systems Holdings, Inc. (Pink Sheets:NCSH), ("NanoChem" or "The Company") and Calgenex Corporation ("Calgenex"), a developer and marketer of novel, patented or patent pending, condition specific dietary supplements and topical over-the-counter (OTC) drugs and personal care products, today provided an update on their upcoming merger, which the companies expect to complete on or around February 29, 2008. Simultaneous with the completion of the merger, the companies also expect to announce a new chief executive officer to lead the newly combined company. After the transaction, the combined entity will do business as Calgenex Corporation and trade on the OTC: Pink Sheets Exchange."
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
